{"id":"placebo-to-match-pioglitazone","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL595","moleculeType":"Small molecule","molecularWeight":"356.45"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebos are inactive substances used as controls in clinical trials to measure the true efficacy of an active drug by comparison. This particular placebo is designed to be indistinguishable from pioglitazone in Phase 3 trials, allowing for blinded assessment of pioglitazone's effects on insulin sensitivity and glucose metabolism in diabetes patients.","oneSentence":"This is an inert placebo formulated to match the appearance and administration of pioglitazone, a thiazolidinedione insulin sensitizer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:43.433Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trials of pioglitazone"}]},"trialDetails":[{"nctId":"NCT06922656","phase":"PHASE4","title":"Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?","status":"NOT_YET_RECRUITING","sponsor":"Dasman Diabetes Institute","startDate":"2025-09-15","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT06336798","phase":"PHASE2","title":"Bioenergetic Effect of Pioglitazone in CLD-PH","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-12-17","conditions":"Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases","enrollment":20},{"nctId":"NCT00179400","phase":"PHASE4","title":"The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2000-12","conditions":"Type 2 Diabetes Mellitus","enrollment":26},{"nctId":"NCT04227093","phase":"PHASE4","title":"Acetazolamide Add-On Therapy to OSA Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2020-01-22","conditions":"Obstructive Sleep Apnea","enrollment":26},{"nctId":"NCT02535832","phase":"PHASE1","title":"Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2015-09","conditions":"Rheumatoid Arthritis, Insulin Resistance","enrollment":16},{"nctId":"NCT00203996","phase":"PHASE4","title":"Polycystic Ovary Syndrome (PCOS) and Sleep Apnea","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2003-09","conditions":"Polycystic Ovary Syndrome, Obstructive Sleep Apnea","enrollment":37},{"nctId":"NCT03910361","phase":"PHASE4","title":"Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2019-04-12","conditions":"Type2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":51},{"nctId":"NCT01931566","phase":"PHASE3","title":"Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-08-01","conditions":"Mild Cognitive Impairment Due to Alzheimer's Disease","enrollment":3494},{"nctId":"NCT02284906","phase":"PHASE3","title":"AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease","status":"TERMINATED","sponsor":"Takeda","startDate":"2015-02-12","conditions":"Mild Cognitive Impairment Due to Alzheimer's Disease","enrollment":40},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01217073","phase":"PHASE2","title":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":685},{"nctId":"NCT01431521","phase":"PHASE1","title":"Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-26","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":31},{"nctId":"NCT00634036","phase":"PHASE2","title":"Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics","status":"COMPLETED","sponsor":"Fernando Holguin","startDate":"2009-10","conditions":"Asthma","enrollment":23},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00397631","phase":"PHASE3","title":"Initial Combination With Pioglitazone Study (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-19","conditions":"Type 2 Diabetes Mellitus","enrollment":520},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT00879970","phase":"PHASE4","title":"Thiazolidinedione Intervention With Vitamin D Evaluation","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1332},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT00683878","phase":"PHASE3","title":"Add-on to Thiazolidinedione (TZD) Failures","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Type 2 Diabetes","enrollment":972},{"nctId":"NCT01703260","phase":"PHASE2","title":"Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-06","conditions":"Nonalcoholic Steatohapatitis","enrollment":20},{"nctId":"NCT00839527","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":685},{"nctId":"NCT00763815","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Diabetes Mellitus Type 2","enrollment":484},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT02678676","phase":"","title":"An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 2","enrollment":3599},{"nctId":"NCT00722917","phase":"PHASE2","title":"Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Takeda","startDate":"2008-07","conditions":"Diabetes Mellitus","enrollment":323},{"nctId":"NCT00086502","phase":"PHASE3","title":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":353},{"nctId":"NCT00736996","phase":"PHASE2","title":"Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2008-11","conditions":"Mild Cognitive Impairment","enrollment":78},{"nctId":"NCT01280123","phase":"PHASE2","title":"Pioglitazone in Early Parkinson's Disease","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2011-03","conditions":"Parkinson's Disease","enrollment":210},{"nctId":"NCT01115712","phase":"PHASE1","title":"Effects of Pioglitazone on Insulin Sensitivity in Healthy Overweight and Obese Males (MK-0000-170)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05","conditions":"Healthy, Overweight, Obesity","enrollment":35},{"nctId":"NCT01103414","phase":"PHASE2","title":"Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Metabolic Solutions Development Company","startDate":"2010-09","conditions":"Type 2 Diabetes","enrollment":356},{"nctId":"NCT00814372","phase":"PHASE2","title":"Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2008-12","conditions":"Type 2 Diabetes Mellitus","enrollment":242},{"nctId":"NCT00787644","phase":"PHASE2","title":"Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)","status":"TERMINATED","sponsor":"University of Vermont","startDate":"2009-01","conditions":"Asthma, Obesity","enrollment":28},{"nctId":"NCT00153166","phase":"PHASE2, PHASE3","title":"ARREST PAD (Peripheral Arterial Disease)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2004-01","conditions":"Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance","enrollment":76},{"nctId":"NCT00641043","phase":"PHASE3","title":"Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-03","conditions":"Diabetes Mellitus, Type 2","enrollment":389},{"nctId":"NCT01230749","phase":"PHASE2","title":"A Study of Multiple Oral Doses of JNJ-41443532 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":89},{"nctId":"NCT00443755","phase":"PHASE2","title":"Effect of Insulin Sensitizer Therapy on Atherothrombotic and Inflammatory Profiles Associated With Insulin Resistance","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2005-08","conditions":"Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome","enrollment":28},{"nctId":"NCT01106690","phase":"PHASE3","title":"The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-06","conditions":"Diabetes Mellitus, Type 2","enrollment":344},{"nctId":"NCT00655863","phase":"PHASE3","title":"Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-07","conditions":"Diabetes Mellitus","enrollment":71},{"nctId":"NCT00328627","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1554},{"nctId":"NCT00432276","phase":"PHASE3","title":"Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":803},{"nctId":"NCT00395512","phase":"PHASE3","title":"Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-11","conditions":"Diabetes Mellitus","enrollment":655},{"nctId":"NCT01289119","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT01456117","phase":"PHASE1","title":"Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-11","conditions":"Healthy","enrollment":61},{"nctId":"NCT00225264","phase":"PHASE3","title":"Efficacy Study of Pioglitazone and Glimepiride on the Rate of Progression of Atherosclerotic Disease.","status":"COMPLETED","sponsor":"Takeda","startDate":"2003-10","conditions":"Diabetes Mellitus","enrollment":458},{"nctId":"NCT00676260","phase":"PHASE2","title":"Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin","status":"COMPLETED","sponsor":"Takeda","startDate":"2002-12","conditions":"Diabetes Mellitus","enrollment":29},{"nctId":"NCT00174993","phase":"PHASE3","title":"Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2001-05","conditions":"Diabetes Mellitus","enrollment":4373},{"nctId":"NCT00521742","phase":"PHASE3","title":"Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2001-03","conditions":"Diabetes Mellitus","enrollment":300},{"nctId":"NCT00331487","phase":"PHASE3","title":"Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-09","conditions":"Diabetes Mellitus","enrollment":719},{"nctId":"NCT00494312","phase":"PHASE4","title":"Safety Study of Pioglitazone Compared To Glyburide on Liver Function","status":"COMPLETED","sponsor":"Takeda","startDate":"2000-10","conditions":"Diabetes Mellitus, Liver","enrollment":2120},{"nctId":"NCT00521820","phase":"PHASE3","title":"Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure","status":"TERMINATED","sponsor":"Takeda","startDate":"2000-06","conditions":"Diabetes Mellitus","enrollment":518},{"nctId":"NCT00762736","phase":"PHASE2","title":"Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-07","conditions":"Diabetes Mellitus","enrollment":704},{"nctId":"NCT00708175","phase":"PHASE4","title":"Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-05","conditions":"Bone Metabolism","enrollment":156},{"nctId":"NCT00286494","phase":"PHASE3","title":"Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-02","conditions":"Diabetes Mellitus","enrollment":493},{"nctId":"NCT00770653","phase":"PHASE3","title":"Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-04","conditions":"Diabetes Mellitus, Dyslipidemias","enrollment":305},{"nctId":"NCT00631007","phase":"PHASE2","title":"A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator","status":"COMPLETED","sponsor":"InteKrin Therapeutics, Inc.","startDate":"2008-02","conditions":"Type 2 Diabetes Mellitus","enrollment":367},{"nctId":"NCT00770640","phase":"PHASE2","title":"Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-08","conditions":"Diabetes Mellitus","enrollment":40},{"nctId":"NCT00770445","phase":"PHASE4","title":"Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-05","conditions":"Diabetes Mellitus","enrollment":121},{"nctId":"NCT00770575","phase":"PHASE2","title":"Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-06","conditions":"Cardiovascular Diseases","enrollment":148},{"nctId":"NCT00770952","phase":"PHASE3","title":"Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-12","conditions":"Diabetes Mellitus","enrollment":91},{"nctId":"NCT00771004","phase":"PHASE2","title":"Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-08","conditions":"Oxidative Stress, Coronary Artery Disease, Type 2 Diabetes","enrollment":63},{"nctId":"NCT00754403","phase":"PHASE4","title":"Efficacy of Pioglitazone and Fortamet Combination Therapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-07","conditions":"Diabetes Mellitus","enrollment":312},{"nctId":"NCT00770497","phase":"PHASE2","title":"Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-03","conditions":"Inflammation, Hypertension","enrollment":172},{"nctId":"NCT00772174","phase":"PHASE3","title":"Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":418},{"nctId":"NCT00227110","phase":"PHASE4","title":"Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2002-10","conditions":"Nonalcoholic Steatohepatitis","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo to match pioglitazone","genericName":"placebo to match pioglitazone","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is an inert placebo formulated to match the appearance and administration of pioglitazone, a thiazolidinedione insulin sensitizer. Used for Control arm in Phase 3 clinical trials of pioglitazone.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}